Ionis Pharmaceuticals Inc (ISI)

38.855
-1.000(-2.51%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    38.855 - 38.855

ISI Overview

Prev. Close
39.855
Day's Range
38.855-38.855
Revenue
875.48M
Open
38.855
52 wk Range
22.37-48.165
EPS
0.052
Volume
0
Market Cap
5.42B
Dividend (Yield)
0.00
(N/A)
Average Vol. (3m)
115
P/E Ratio
804.07
Beta
0.548
1-Year Change
53.52%
Shares Outstanding
141,941,338
Next Earnings Date
-
What is your sentiment on Ionis Pharma?
or
Market is currently closed. Voting is open during market hours.

Ionis Pharmaceuticals Inc News

Ionis Pharmaceuticals Inc Analysis

Ionis Pharmaceuticals Inc Company Profile

Ionis Pharmaceuticals Inc Company Profile

Employees
660
  • Type:Equity
  • Market:Germany
  • ISIN:US4622221004
  • WKN:A2ACMZ

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Read More

Analyst Price Target

Average50.263 (+27.35% Upside)
High92
Low24
Price39.47
No. of Analysts19
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy
  • What’s about this stock? Any new therapies are coming out?
    0
    • I think shareholders needs a therapy now. BIIB / IONIS Tofersen (BIIB067) Phase 3 test did unsuccesful
      0
  • Absolutely underrated stock. See you in ten years or this fall when the product in cooperation with Biogen comes out
    0
    • Added 4000 at 34.4
      1
      • nice after market move!
        0
        • Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
          0
          • CARLSBAD, Calif., March 22, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease (HD). The decision was based on the results of a pre-planned review of data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC). While there were no new or emerging safety signals identified for tominersen, the iDMC made its recommendation based on the investigational therapy's potential benefit/risk profile for study participants. Participants will continue to be followed for safety and clinical outcomes.
            0
            • this stock doesn't know what a green day looks like.
              0
              • ㅜㅜ~
                0